Irresponsible antibiotic promotion may speed Superbug spread, says WHO

By Gareth Macdonald

- Last updated on GMT

Related tags Antibiotic resistance

Pharma promotion exacerbating Superbug problems, says WHO
Pharma promotion exacerbating Superbug problems, says WHO
Improper antibiotic use is driving the ‘Superbug’ epidemic but irresponsible promotional may be exacerbating the problem according to the WHO.

The main focus of last Sunday’s European Antibiotic Awareness Day (EAAD) was promoting the idea that appropriate, as-prescribed use of antibiotics can slow the spread of resistant bacteria in the continent.

But, while patient education clearly has a major role to play, drug industry economics may encourage marketing practices that fuel the superbug epidemic according to Danilo Lo Fo Wong, Senior Advisor on Antimicrobial Resistance of WHO Regional Office for Europe.

Developing new antibiotics is a very complex process which implies substantial economic investments. As antibiotic resistance emerges faster than ever before, the window for earning back the investment and making profit has become very narrow.

This could lead to intensive marketing strategies aimed at increasing antibiotic prescription and consumption," ​Dr Wong continued, citing promotional practices aimed at doctors and the payment of financial incentives to pharmacists as sales strategies that could “stimulate the unnecessary use and misuse of antibiotics by patients​.”

He also suggested that direct advertising to patients may also “create an unnecessary demand for antibiotics​.”

New business model

Instead, the WHO wants the pharmaceutical manufacturing industry to develop new antibiotics - through initiatives like BSAC, IMI, JPI AMR and ReAct - and by trying to uncouple return on investment from sales.

Wong told us that: “Delinking return on investment from sales… would likely involve some form of public funding that rewards the most promising research in various stages of development. This would mean that by the time of completion and distribution of a successfully developed new antibiotic, the investment has been paid off.  

Such a theoretical business model has not been fully conceptualized nor developed yet and will require much more discussion with key partners in private and public sectors. However, this can be the way forward if we want to limit the misuse of antibiotics and that novel antibiotics will be made globally accessible and affordable.

As another positive step, Wong suggested that “clear warnings on antibiotic packaging that they should be taken only as prescribed by a doctor…would help consumers understand that antibiotic work against bacteria, not viruses and that self-prescription of antibiotics contribute to developing resistance​.”

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us